In conclusion, our study demonstrated that LINC00460 served as a CRC immune regulator through the LINC00460/miR-186-3p/MYC feedback loop, providing a novel therapeutic strategy and target for CRC. Here, LINC00460 is linked to colorectal carcinoma.